Ozempic has already revolutionized the fight against overweight. Now he is undergoing treatment for cardiovascular disease


“Biggest Medical Advance Since Statins.” that, said at the European Obesity Congress, big words. After all, statins are one of the central tools in the modern medical fight against cardiovascular disease. Let us remember that diseases are the biggest cause of death in the world.

I mean, it sounded amazing before I found out they were talking about Ozempic.

Ozempic? But isn’t it for weight loss? Indeed. Semaglutide (the active ingredient behind ‘Ozempic’ and ‘Wegovi’) is a diabetes drug that, in recent years, has caused an international revolution in the way we understand overweight. The point is that According to a large international team of researchers“Reduces the risk of heart attack and benefits the cardiovascular health of millions of adults.”

The information. Over four years, researchers recruited more than 17,000 people with cardiovascular problems from 47 countries: 8,803 patients were randomly assigned to semaglutide and another 8,801 to placebo. The results They were amazingly clean.: Participants taking semaglutide had a 20% lower risk of heart attack, stroke, or death from heart disease.

The team’s conclusion goes further: According to their research, semaglutide brings cardiovascular benefits to users regardless of their initial weight or weight gain.

The case of statins and side effects: The latest major health controversy that affected nearly a million people

What does all this mean? For researchers (For example, John Dinfield, director of the National Institute for Cardiovascular Outcomes Research at University College London), “Research has shown that the drug should be routinely prescribed to treat cardiovascular disease and that millions of people across the UK may be taking the drug.” medicine in the coming years.

And the idea is suggestive. Some haste, but suggestive. At the end of the day, we can see how all these drugs are bringing about a real revolution in the medical field that we could not have imagined.

In this case, As Jason Halford explainsThe president of the European Association for the Study of Obesity, if the data are confirmed, wider prescribing of semaglutide could be “economically beneficial” for the health system.

But the story goes further: We are not really aware of the effects these drugs are going to have. I take this for granted because, even if progress in the field stops today, what we have already achieved has the potential to change everything as it becomes widespread. And we’re going to see it in the coming years.

Picture | Chemist 4U

In Xataka | Ozempic for weight loss: its effects and risks are beyond debate, according to science